Navigation Links
CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal
Date:2/20/2009

PALO ALTO, Calif., Feb. 20 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that its board of directors has thoroughly reviewed and rejected the previously announced unsolicited proposal from Astellas Pharma Inc. to acquire CV Therapeutics at a price of $16.00 per share.

After careful consideration of the proposal with its independent financial and legal advisors, the CV Therapeutics board concluded that the Astellas proposal significantly undervalues the company and is not in the best interests of CV Therapeutics and its stockholders. The board had previously rejected the same proposal on November 21, 2008, when Astellas approached the company privately.

"CV Therapeutics has a strategic plan in place which we believe will enhance shareholder value. Moreover, we have always been, and remain, receptive to opportunities to further enhance shareholder value. Executing on our strategic plan enabled us to achieve outstanding results in 2008, with multiple regulatory approvals, record revenues and two exceptional strategic transactions. This strong record of product approvals, which exceeds that of many pharma companies over the last several years, has allowed the company to establish a solid cash position. The full promotional launch of the improved U.S. Ranexa labeling is just beginning, the introduction of Ranexa in Europe is imminent, and Lexiscan is showing real growth in the marketplace. Accordingly, we expect 2009 to be another outstanding year, highlighted by increasing revenues and pipeline advancement, for example with CVT-3619," said Louis G. Lange, chairman and chief executive officer of CV Therapeutics.


    Following is the text of the letter being sent by CV Therapeutics today
    to Masafumi Nogimori, president and chief executive officer of Astellas
    Pharma:

 
'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
2. Sopherion Therapeutics Secures $55 Million in Series C Funding
3. Amicus Therapeutics Announces Change to Board of Directors
4. Opsona Therapeutics Closes EUR18M Funding
5. Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health
6. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
7. United Therapeutics to Announce 2008 Fourth Quarter and Annual Financial Results Before Market Open on Tuesday, February 17, 2009
8. Northwest Biotherapeutics Secures $700,000 Equity Financing
9. iCo Therapeutics Closes $1.3 Million Private Placement
10. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
(Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
(Date:1/14/2014)... 2014 During the 1600’s through the 1800’s ... Doctor’s Plague.” In this time period, doctors did not know ... times, to the death of vulnerable patients. In the same ... they may be unwittingly transmitting herpes viruses to their patients. ...
(Date:1/14/2014)... Holloway America today announced an addition to ... (MTRs) for all pressure vessels and tank parts the ... important for equipment that must meet ASME, CE, PED, ... functionality that allows authorized users to quickly locate and ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... Symbol: MS , , , ... Medical Corp. (TSX: MS), today announced that the University of Alberta , a major shareholder ... , , Certain employees, officers ... Alberta . , , , ...
... Smartfield, ... was approved for $250,000 for completion and commercialization of their SmartCrop® technology. SmartCrop is ... , ... 30, 2010 -- Smartfield, Inc. is an information company that develops and ...
... ATLANTA , April 29 Xoft, Inc., developer of ... therapy directly to cancer sites with minimal radiation exposure to surrounding ... for the treatment of skin cancer. The announcement was made here ... April 29-May 1 . , ...
Cached Biology Technology:BioMS Medical updates University of Alberta equity position 2$250,000 Awarded to Smartfield, Inc. of Lubbock, TX by the Texas Emerging Technology Fund 2Xoft's Electronic Brachytherapy Hits Milestone With 10 New Skin Cancer Installations 2Xoft's Electronic Brachytherapy Hits Milestone With 10 New Skin Cancer Installations 3Xoft's Electronic Brachytherapy Hits Milestone With 10 New Skin Cancer Installations 4
(Date:4/22/2014)... 2014 Scientists from the Florida campus of The ... that plays a critical but previously unknown role in ... showed a novel role for a protein known as ... eLife , a publisher supported by the Howard ... Wellcome Trust. , "This is a critical building block ...
(Date:4/22/2014)... nanotechnology expert will present a poster titled ... 7th International Nanotoxicology Congress to be held ... Monita Sharma will outline a strategy consistent with the ... " Toxicity Testing in the 21st Century: A Vision ... methods involving human cells and cell lines for mechanistic ...
(Date:4/22/2014)... Experimental Biology (FASEB) has released updated factsheets ... the National Institutes of Health (NIH) benefits each of ... pleased to make these factsheets available to help citizens ... state," said FASEB President, Margaret K. Offermann, MD, PhD. ... research funding, investing $29.2 billion in FY 2013 in ...
Breaking Biology News(10 mins):Scientists identify critical new protein complex involved in learning and memory 2
... This press release is available in French ... and men contribute equally to the lineage of contemporary populations? ... polygamy or monogamy? To answer these questions, Dr. Damian Labuda, ... a professor at the Department of Pediatrics of the Universit ...
... professor of chemistry at New Jersey Institute of ... patent today for a novel composition of matter. ... (US Patent Number 7,670,684) discloses a new self-contained ... comprised of organic scaffolds with metal centers, which ...
... worldwide. It is the most common form of age-related dementia, ... no cure, and the available drugs only help to relieve ... characteristic changes in the brains of Alzheimer,s patients is the ... curing or at least slowing the disease lies in developing ...
Cached Biology News:Modern man found to be generally monogamous, moderately polygamous 2NJIT researcher awarded patent for hydrophobic, corrosion-resistant coating 2The sea squirt offers hope for Alzheimer's sufferers 2
Candida (IgG) -Ab EIA Sample Size: 5 l...
Candida (IgA) -Ab EIA Sample Size: 5 l...
Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
... the first higher plant to be fully ... primary model organism for gene expression research ... microarray is derived from the ATH1 v.5 ... (TIGR) and from the Arabidopsis MPSS database ...
Biology Products: